BC Week In Review | May 26, 2014
Clinical News

ALD-401: Phase II data

The double-blind, U.S. Phase II RECOVER-Stroke trial in patients with neurological damage arising from an ischemic stroke showed that an intracarotid infusion of 3 mL ALD-401 given 13-19 days post-stroke missed the primary endpoint of...
BioCentury | Oct 7, 2013
Finance

3Q Stock Wrap-Up: Make it a double

For the second time this year, all market cap segments closed the quarter in the black. Large caps valued at $5 billion and above gained ground for the fifth consecutive quarter. They added 12%, and...
BC Week In Review | Sep 23, 2013
Company News

Cytomedix dermatology news

Cytomedix will restructure R&D to reduce cash burn and focus on commercializing AutoloGel for chronic wound care. By year end, the company will "substantially" conclude its financial support of the Phase II RECOVER-Stroke trial with...
BC Week In Review | Oct 22, 2012
Clinical News

ALD-401: Interim Phase II data

Interim data from 10 patients in the double-blind, placebo-controlled, U.S. Phase II RECOVER-Stroke trial showed that an intracarotid infusion of 3 mL ALD-401 given 13-19 days post-stroke was safe with no severe adverse events reported....
BC Week In Review | May 21, 2012
Clinical News

ALD-401: Phase II ongoing

Cytomedix said an independent DSMB recommended continuation of the double-blind, placebo-controlled, U.S. Phase II RECOVER-Stroke trial based on a review of safety data from the first 10 patients. The trial is evaluating an intracarotid infusion...
BC Week In Review | Feb 13, 2012
Company News

Aldagen, Cytomedix deal

Wound and tissue repair company Cytomedix acquired regenerative cell therapy play Aldagen in a stock deal valued at about $16 million. Aldagen shareholders, who will own 17% of the combined company, are also eligible for...
BC Extra | Feb 9, 2012
Company News

Cytomedix acquires Aldagen

Wound and tissue repair company Cytomedix Inc. (OTCBB:CMXI) acquired regenerative cell therapy play Aldagen Inc. (Durham, N.C.) in a stock deal valued at about $16 million. Aldagen shareholders, who will own 17% of the combined...
BC Week In Review | Jun 13, 2011
Clinical News

ALD-401: Phase II started

Aldagen began a double-blind, sham-controlled, U.S. Phase II trial to evaluate an intracarotid infusion of 3 mL ALD-401 given 13-19 days post-stroke in about 100 patients. Aldagen Inc. , Durham, N.C.   Product: ALD-401   Business:...
BioCentury | Apr 11, 2011
Finance

Second time no charm

Cell therapeutic company Aldagen Inc. , which apparently is running very low on cash, last week withdrew its IPO for a second time. The company withdrew an IPO in 2008 and then refiled in 2009. In...
BC Extra | Apr 6, 2011
Financial News

Aldagen pulls IPO

Aldagen Inc. (Durham, N.C.) withdrew its IPO due to market conditions. In July 2010, the company amended its IPO to raise $40 million. Aldagen is preparing to begin a Phase II trial for ALD-401 to...
Items per page:
1 - 10 of 11